

ICD-O

International Classification of Diseases for Oncology

Third Edition

Editors

April Fritz
Constance Percy
Andrew Jack
Kanagaratnam Shanmugarathnam
Leslie Sobin
D. Max Parkin
Sharon Whelan



World Health Organization
Geneva



International Classification of Diseases for Oncology

Third Edition

Editors

April Fritz

National Cancer Institute, Bethesda, MD, USA

Constance Percy

National Cancer Institute, Bethesda, MD, USA

Andrew Jack

Leeds Teaching Hospitals, Leeds, England

Kanagaratnam Shanmugaratnam

National University of Singapore, Singapore

Leslie Sobin

Armed Forces Institute of Pathology, Washington, DC, USA

D. Max Parkin

International Agency for Research on Cancer, Lyon, France

Sharon Whelan

International Agency for Research on Cancer, Lyon, France



World Health Organization
Geneva
2000

Reprinted 2001, 2005, 2007, 2009, 2012

WHO Library Cataloguing-in-Publication Data

International classification of diseases for oncology / editors, April Fritz...[et al.] – 3rd ed.

1.Neoplasms - classification I.Fritz, April II.ICD-O

ISBN 92 4 154534 8 (NLM Classification: QZ 15)

The World Health Organization welcomes requests for permission to reproduce or translate its publications, in part or in full. Applications and enquiries should be addressed to the Office of Publications, World Health Organization, Geneva, Switzerland, which will be glad to provide the latest information on any changes made to the text, plans for new editions, and reprints and translations already available.

© World Health Organization 2000

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. All rights reserved.

The editors alone are responsible for the views expressed in this publication.

Printed in Malta

TABLE OF CONTENTS

Dedication to Calum Muir	v
Acknowledgements	vi
Introduction	1
Historical Background	3
Differences between ICD-O and ICD-10	5
Structure and Format of ICD-O, Third Edition	8
Coding Guidelines for Topography and Morphology	19
Summary of Principal Rules for Using ICD-O	20
Coding Guidelines for Topography	23
Coding Guidelines for Morphology	27
Multiple Primary Neoplasms	35
Basis of Diagnosis	38
The WHO Grading System for Central Nervous System Tumors and the ICD-O Grade Code	39
References	41
Numerical Lists	43
Topography	45
5th Digit Behavior Code for Neoplasms	66
6th Digit Code for Histologic Grading and Differentiation	67
6th Digit Code for Immunophenotype Designation for Lymphomas and Leukemias	67
Morphology	69
Alphabetic Index	105
Appendices	
1: New ICD-O, Third Edition, Codes	219
2: New Morphology Terms and Synonyms	227
3: Terms That Changed Morphology Code	235
4: Terms That Changed from Tumor-like Lesions to Neoplasms	238
5: Terms Deleted from ICD-O, Third Edition	238
6: Terms That Changed Behavior Code	239

DEDICATION

CALUM MUIR

1930 – 1995

This Third Edition of the *International Classification of Diseases for Oncology* (ICD-O) is dedicated to the memory of Dr Calum Muir.

Calum Muir was an editor of the Second Edition of ICD-O. As a pathologist, he did much to assemble the new morphologic terms and the latest classifications for lymphomas, leukemias and brain tumors. His contacts with cancer registries throughout the world helped to implement ICD-O worldwide.

After his retirement from the International Agency for Research on Cancer, initially as Chief of the Unit of Epidemiology and later as its Deputy Director, Calum Muir became the Director of Cancer Registration for Scotland. He was instrumental in founding the International Association of Cancer Registries in 1966, serving as Deputy Secretary from 1972 to 1990 and as President from 1992 until his death.

Calum Muir's spirit and devotion to accurate and complete classification of neoplasms lives on in this edition.

ACKNOWLEDGEMENTS

We are grateful to the following individuals and their institutions for their contributions to this edition of ICD-O.

Dr Timothy Coté, National Cancer Institute, Bethesda, MD, USA

Mme Catherine Exbrayat, Registre des Cancers de l'Isère, Isère, France

Professor Ekkehard Grundmann, Gerhard Domagk Institut für Pathologie, Münster Universität, Münster, Germany

Professor Paul Hermanek, Chirurgische Klinik mit Poliklinik der Universität Erlangen-Nürnberg, Erlangen, Germany

Dr Elaine Jaffe, National Cancer Institute, Bethesda, MD, USA

Dr Paul Kleihues, International Agency for Research on Cancer, Lyon, France

Dr Franco Rilke, Società Italiana di Cancerologia, Milan, Italy

Dr James Vardiman, University of Chicago, Chicago, IL, USA

Mrs Annette Hurlbut, Fulton, NY, USA

We greatly appreciate the input of the expert groups that provided valuable background material for the development of this Third Edition and gave the editors the benefit of their advice on the field-trial edition:

European Network of Cancer Registries (ENCR) Working Group on the coding of haematological malignancies and lymphomas

Dr Renée Otter, Comprehensive Cancer Centre North, Groningen, The Netherlands

Dr Aurora Astudillo, Hospital General de Asturias, Oviedo, Spain

Professor Paule Marie Carli, Registre des Hémopathies Malignes en Côte d'Or, Dijon, France

Dr Andrew Jack, Leukaemia Research Fund, University of Leeds, Leeds, England

Dr Han Van Krieken, The Academic Hospital, Leiden, The Netherlands

International Society of Pediatric Oncology (SIOP) Working Group

Professor Jillian M. Birch, CRC Paediatric and Familial Cancer Research Group, Manchester, England

Dr James Ironside, National Creutzfeldt-Jakob Disease Surveillance Unit, Western General Hospital, Edinburgh, Scotland

Dr Anna M. Kelsey, Royal Manchester Children's Hospital, Manchester, England

Professor Dietmar Schmidt, Institut für Pathologie, Mannheim, Germany

We would like to thank the cancer registries and the pathologists and data collectors associated with these registries who put an immense amount of careful work into the field testing of ICD-O, Third Edition.

Australia, New South Wales
Australia, South
Australia, Victoria
Belarus
Belgium
Brazil, Campinas
Brazil, Porto Alegre
Canada, British Columbia
Canada, Manitoba
Canada, Ontario
Canada, Ontario, Princess
Margaret Hospital
Canada, Nova Scotia
China, Beijing
China, Qidong
Cuba
Czech Republic
Ecuador, Quito
Egypt, Alexandria
France, Haut-Rhin
France, Hémopathies Malignes
en Côte d'Or
France, Hérault
France, Tarn
Germany, Baden-Württemberg
Germany, Federal States of
Berlin
Germany, National Childhood
Guinea, Conakry
Indonesia

Italy, Ferrara
Italy, Macerata
Italy, Ragusa
Italy, Romagna
Japan, Hiroshima
Japan, Nagasaki
Japan, Osaka
Lithuania
Malta
Netherlands, Amsterdam
New Zealand
Pakistan, Karachi
Peru, Lima
Peru, Trujillo
Philippines, Manila
Philippines, Rizal
Poland, Kielce
Saudi Arabia
Singapore
Slovenia
South Africa
Spain, Asturias
Spain, Granada
Spain, Mallorca
Spain, Murcia
Sweden, Gothenburg
Thailand, Bangkok
Thailand, Chiang Mai
Trinidad and Tobago

Uganda, Kampala
United Kingdom, East Anglia
United Kingdom, Northern and
Yorkshire
United Kingdom, Oxford,
National Childhood
USA, Florida, Flagler Hospital
USA, Georgia, Medical Center
of Central Georgia
USA, Missouri, Liberty
Hospital
USA, Ohio, Upper Valley
Medical Center
USA (SEER), Atlanta
USA (SEER), Connecticut
USA (SEER), Detroit
USA (SEER), Hawaii
USA (SEER), Iowa
USA (SEER), Los Angeles
USA (SEER), New Mexico
USA (SEER), Northern
California
USA (SEER), Seattle/Puget
Sound
USA (SEER), Utah
USA, Texas, College Station
Medical Center
Viet Nam, Ho Chi Minh

We also gratefully acknowledge the many individuals, institutions, and registries that took the time to

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_25016

